CDEK
← All drugs Report issue

pagoclone

Small moleculeexperimental

Pagoclone is an anxiolytic agent from the cyclopyrrolone family, related to better-known drugs such as the sleeping medication zopiclone. It was synthesized by a French team working for Rhone-Poulenc & Rorer S.A. Pagoclone belongs to the class of nonbenzodiazepines, which have similar effects to the older benzodiazepine group, but with quite different chemical structures. It was never commercialised. — Wikipedia

Clinical trial activity

4 trials · 3 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
3
Phase 3
1
Phase 4
0

Earliest trial started Apr 1, 2005 (NCT00239915)

Timeline

2000s

  1. Jan 1, 2005

    Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CC(C)CCC(=O)CC1c2ccccc2C(=O)N1c1ccc2ccc(Cl)nc2n1
Mol. weight
407.9 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Racemic Mixture
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 2-(7-chloro-1.8-naphthyridin-2-yl)-2,3-dihydro-3-(5-methyl-2-oxohexyl)-1h-isoindol-1-one
  • ip-456
  • ip-456
  • pagoclone
  • pagoclone
  • pagoclone
  • pagoclone
  • pagoclone
  • rp 62955
  • rp-62955
  • rp-62955

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT00830154Phase 2/Phase 3 (Phase 3)Feb 1, 2009Endo Pharmaceuticals, Teva
NCT00370981Phase 2Jul 1, 2006Endo Pharmaceuticals
NCT00216255Phase 2Apr 1, 2005Endo Pharmaceuticals
NCT00239915Phase 2Apr 1, 2005Pharmacology Research Institute
Showing 4 of 4 trials
Page 1 / 1

Organizations

Research & Development (3)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Endo PharmaceuticalsFor profit3322005
Pharmacology Research InstituteFor profit1112005
TevaFor profit1012009
3 organizations
Page 1 / 1